• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Drugs, money and society (Part II).毒品、金钱与社会(第二部分)。
Br J Clin Pharmacol. 2010 Sep;70(3):342-5. doi: 10.1111/j.1365-2125.2009.03569.x.
2
Pharmacoeconomics: NICE's approach to decision-making.药物经济学:英国国家卫生与临床优化研究所的决策方法。
Br J Clin Pharmacol. 2010 Sep;70(3):346-9. doi: 10.1111/j.1365-2125.2009.03589.x.
3
From NCE to NICE: the role of pharmacoeconomics.从新化学实体到优质药物:药物经济学的作用
Br J Clin Pharmacol. 2010 Sep;70(3):317-9. doi: 10.1111/j.1365-2125.2010.03708.x.
4
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?基于价值的定价、研究与开发以及患者准入方案。英国会做对还是做错?
Br J Clin Pharmacol. 2010 Sep;70(3):360-6. doi: 10.1111/j.1365-2125.2010.03740.x.
5
In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.在这种情况下:一家生产常用药物仿制药的制药公司生产了一种在特定服务中广泛使用的专利药物的仿制药。回应。
N Z Bioeth J. 2003 Oct;4(3):22-3.
6
Pharmaceutical economy and the economic assessment of drugs in France.法国的药物经济学与药物经济评估
Soc Sci Med. 1997 Aug;45(4):635-43. doi: 10.1016/s0277-9536(96)00402-9.
7
Pharmacoeconomics is coming of age.药物经济学正在走向成熟。
Clin Pharmacol Ther. 2008 Aug;84(2):188-90. doi: 10.1038/clpt.2008.120.
8
Spending on pharmaceuticals in Italy: macro constraints with local autonomy.意大利的药品支出:宏观限制与地方自主权
Value Health. 2003 Jul-Aug;6 Suppl 1:S31-45. doi: 10.1046/j.1524-4733.6.s1.4.x.
9
Public drug expenditure in the Republic of Ireland.爱尔兰共和国的公共药物支出。
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):239-45. doi: 10.1586/erp.10.23.
10
Implementing pharmacoeconomic guidelines in Latin America: lessons learned.在拉丁美洲实施药物经济学指南:经验教训
Value Health. 2011 Jul-Aug;14(5 Suppl 1):S3-7. doi: 10.1016/j.jval.2011.05.036.

引用本文的文献

1
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.全球健康困境:孤儿病与罕见病、孤儿药与孤儿患者
World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.
2
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?基于价值的定价、研究与开发以及患者准入方案。英国会做对还是做错?
Br J Clin Pharmacol. 2010 Sep;70(3):360-6. doi: 10.1111/j.1365-2125.2010.03740.x.

本文引用的文献

1
NICE wobbles.英国国家卫生与临床优化研究所(NICE)摇摆不定。
J R Soc Med. 2009 Jun;102(6):212-3. doi: 10.1258/jrsm.2009.09k031.
2
The decade of NICE.英国国家卫生与临床优化研究所的十年。
Lancet. 2009 Jul 25;374(9686):351-2. doi: 10.1016/S0140-6736(09)60616-4. Epub 2009 Apr 23.
3
Pharmacoeconomics is coming of age.药物经济学正在走向成熟。
Clin Pharmacol Ther. 2008 Aug;84(2):188-90. doi: 10.1038/clpt.2008.120.
4
Pharmacoeconomics comes of age?药物经济学走向成熟?
Clin Pharmacol Ther. 2008 Aug;84(2):279-80. doi: 10.1038/clpt.2008.122. Epub 2008 Jun 18.
5
Risk sharing and payment by results.风险分担与按结果付费。
Clin Pharmacol Ther. 2008 May;83(5):666-7. doi: 10.1038/clpt.2008.15.
6
Value based pricing for NHS drugs: an opportunity not to be missed?英国国家医疗服务体系(NHS)药品的基于价值的定价:一个不容错过的机遇?
BMJ. 2008 Feb 2;336(7638):251-4. doi: 10.1136/bmj.39434.500185.25.
7
NICE vindicated in UK's High Court.英国高等法院判定英国国家卫生与临床优化研究所(NICE)胜诉。
Lancet. 2007 Aug 18;370(9587):547-8. doi: 10.1016/S0140-6736(07)61271-9.
8
Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?英国的神经心理治疗学:英国国家卫生与临床优化研究所(NICE)对处方有何影响?
CNS Drugs. 2004;18(1):1-12. doi: 10.2165/00023210-200418010-00001.
9
Publication bias in health economic studies.卫生经济学研究中的发表偏倚。
Pharmacoeconomics. 1997 Mar;11(3):289-92.
10
Is there a need for an independent centre for pharmacoeconomics in the UK?英国是否需要一个独立的药物经济学中心?
Pharmacoeconomics. 1994 Feb;5(2):93-100. doi: 10.2165/00019053-199405020-00003.

毒品、金钱与社会(第二部分)。

Drugs, money and society (Part II).

机构信息

Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

出版信息

Br J Clin Pharmacol. 2010 Sep;70(3):342-5. doi: 10.1111/j.1365-2125.2009.03569.x.

DOI:10.1111/j.1365-2125.2009.03569.x
PMID:20716232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2949904/
Abstract

Pharmacoeconomics started as marketing but has developed into a valuable tool in the fuller assessment of drug therapies. Its principles are now widely accepted, and many countries have government-funded agencies with responsibility for its application, most notably the National Institute for Health and Clinical Excellence in England. Many clinical pharmacologists are active in this area, and the discipline itself is part of the clinical pharmacology trainees' curriculum. Further developments will include value-based pricing and its use in cost sharing arrangements between health service and manufacturers.

摘要

药物经济学最初是作为市场营销的一个分支,但现已发展成为药物治疗全面评估的一个有价值的工具。其原理现已被广泛接受,许多国家都设有负责其应用的政府资助机构,其中最著名的是英国的国家卫生与临床优化研究所。许多临床药理学家活跃在该领域,该学科本身也是临床药理学家培训课程的一部分。进一步的发展将包括基于价值的定价及其在卫生服务机构和制造商之间的成本分担安排中的应用。